Acadia Pharmaceuticals financials
$20.22−1.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $308.0M | $268.1M | $284.0M | $278.6M | $264.6M | $244.3M | $259.6M | $250.4M | $242.0M | $205.8M | $231.0M | $211.7M |
| Gross profit | $279.6M | $243.3M | $257.8M | $257.0M | $243.8M | $223.9M | $237.8M | $231.5M | $223.7M | $182.9M | $213.2M | $197.1M |
| Gross margin | 90.8% | 90.8% | 90.8% | 92.2% | 92.2% | 91.7% | 91.6% | 92.5% | 92.5% | 88.8% | 92.3% | 93.1% |
| Operating income | $37.8M | -$4.6M | $17.4M | $35.8M | $32.4M | $19.3M | $7.0M | $31.6M | $30.4M | $15.2M | $34.9M | -$57.8M |
| Net income | $31.5M | $3.6M | $273.6M | $71.8M | $26.7M | $19.0M | $143.7M | $32.8M | $33.4M | $16.6M | $45.8M | -$65.2M |
| Net margin | 10.2% | 1.4% | 96.3% | 25.8% | 10.1% | 7.8% | 55.4% | 13.1% | 13.8% | 8.0% | 19.8% | −30.8% |
| Diluted EPS | $0.18 | $0.02 | $1.58 | $0.42 | $0.16 | $0.11 | $0.86 | $0.20 | $0.20 | $0.10 | $0.28 | $-0.40 |
| EBITDA | $35.5M | -$1.6M | $20.3M | $38.7M | $29.9M | $22.2M | $12.2M | $34.2M | $33.0M | $20.7M | $34.9M | -$56.1M |
| Operating cash flow | $100.8M | $34.0M | -$48.7M | $74.3M | $64.0M | $20.3M | $40.4M | $63.2M | $25.0M | $29.1M | $85.4M | -$59.0M |
| Free cash flow | $95.7M | $28.8M | -$52.7M | $73.9M | $63.7M | $20.3M | $39.9M | $63.2M | $25.0M | $29.1M | $85.4M | -$59.0M |
| Diluted shares | 172.9M | 172.7M | 172.7M | 170.7M | 168.7M | 167.7M | 166.5M | 166.2M | 166.2M | 166.6M | 163.7M | 164.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $385.0M | $282.2M | $177.7M | $258.0M | $253.6M | $217.7M |
| Short-term investments | $571.5M | $569.2M | $642.0M | $589.0M | $508.4M | $463.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B |
| Total liabilities | $436.3M | $357.2M | $336.8M | $413.5M | $403.2M | $367.1M |
| Shareholders' equity | $1.31B | $1.25B | $1.23B | $917.3M | $822.4M | $765.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology